Objective To evaluate the efficacy of butylphthalide injection combined with rosuvastatin calcium tablets for patients with acute progressive cerebral infarction and its impact on high sensitivity C reactive protein (hs-CRP) and neurological function.
Methods A total of 120 patients with acute progressive cerebral infarction were divided into two groups according to random number table method. The control group was given rosuvastatin calcium tablets, while the study group received butylphthalide injection and rosuvastatin calcium tablets. Clinical effects, hs-CRP level, National Institutes of Health Stroke Scale(NIHSS)score, modified mental state scale(MMSR)score, homocysteine(Hcy), tumor necrosis factor-α(TNF-α), low density lipoprotein cholesterol(LDL-C).
Results After treatment, the total effective rate of the study group was higher than that of the control group(P < 0.05). The NIHSS score of the study group was lower, and MMSR score was higher than that of the control group, and Hcy, hs-CRP, TNF-α and LDL-C levels in the study group were lower than that of the control group(P < 0.05).
Conclusion Butylphthalide injection combined with rosuvastatin for patients with acute progressive cerebral infarction can improve clinical outcomes, improve neurological and cognitive function, reduce Hcy, hs-CRP, TNF-α and LDL-C levels.
DownLoad: